Everything below concerns angiotensin IV. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Jaw pain and neuropathy Loose teeth Mucosal swelling Erythema Suppuration Soft tissue ulceration persisting for more than 8 weeks Trismus Non-healing extraction sockets Paraesthesia or numbness in the jaw Bad breath Exposed necrotic jaw bone
Toxicological evaluation of active substances Overall and specific migration testing Assessment of reaction products and impurities Evaluation of intended and foreseeable use Control of microbial hazards Labelling of non-edible components Protection against accidental ingestion Stability during manufacturing, transport, and storage Disposal, recycling, and environmental considerations Reduced-oxygen and antimicrobial systems must not replace required hygiene, processing, refrigeration, shelf-life controls, or microbiological testing.
. The origin of this minimum conductivity is still unclear. However, rippling of the graphene sheet or ionized impurities in the SiO2 substrate may lead to local puddles of carriers that allow conduction. Several theories suggest that the minimum conductivity should be
== Sources == Furlow, John J. (1997). "Betula". In Flora of North America Editorial Committee (ed.). Flora of North America North of Mexico (FNA). Vol. 3. New York and Oxford: Oxford University Press – via eFloras.org, Missouri Botanical Garden, St. Louis, Missouri and Harvard University Herbaria, Cambridge, Massachusetts. Li, Pei-chun; Skvortsov, Alexei K. "Betula". Flora of China. Vol. 4 – via eFloras.org, Missouri Botanical Garden, St. Louis, Missouri and Harvard University Herbaria, Cambridge, Massachusetts. Grimshaw, John (2009). New Trees, Recent introductions to cultivation. Kew Publishing, RBG Kew. pp. 163–174. Chisholm, Hugh, ed. (1911). "Birch" . Encyclopædia Britannica. Vol. 3 (11th ed.). Cambridge University Press. Jonczak, Jerzy; Jankiewicz, Urszula; Kondras, Marek; Kruczkowska, Bogusława; Oktaba, Lidia; Oktaba, Jarosław; Olejniczak, Izabella; Pawłowicz, Edyta; Polláková, Nora; Raab, Thomas; Regulska, Edyta; Słowińska, Sandra; Sut-Lohmann, Magdalena (December 2020). "The influence of birch trees (Betula spp.) on soil environment – A review". Forest Ecology and Management. 477 118486. Bibcode:2020ForEM.47718486J. doi:10.1016/j.foreco.2020.118486.
In chemistry, particularly in biochemistry, a fatty acid is a carboxylic acid with an aliphatic chain, which is either saturated or unsaturated. Most naturally occurring fatty acids have an unbranched chain of an even number of carbon atoms, from 4 to 28. Fatty acids are a major component of the lipids (up to 70% by weight) in some species such as microalgae but in some other organisms are not found in their standalone form, but instead exist as three main classes of esters: triglycerides, phospholipids, and cholesteryl esters. In any of these forms, fatty acids are both important dietary sources of fuel for animals and important structural components for cells.
Sources: en.wikipedia.org
== Mechanics of Micronization == The size reduction achieved by mechanical micronization depends on both the mill and the material being ground. The breakage behaviour of a material can be characterised by material parameters derived from single-particle impact tests, which quantify a particle's resistance to fracture and the minimum specific energy it can absorb without breaking; these allow the breakage probability of different materials to be described by a common master curve.
== Diseases == There are some indications that NatB might N-terminally acetylate α-synuclein, a protein involved in Parkinson's disease. α-synuclein is a potential match for NatB enzymatic activity, as the protein starts with MD. N-terminal acetylation of α-synuclein has been found to stabilize the protein and regulate the neuronal toxicity level. NatB is also found to be essential for shutoff activity of PA-X, a protein from Influenza A virus. PA-X influences the gene expression and the immune response in a host, and NatB contributes by shutting off the RNA replication of the virus, even though the mechanism behind this is not known. There are some cancer related phenotypes where NAA20 expression was upregulated in hepatocarcinoma and liver cancer. NAA20 expression was also upregulated in by triple-negative breast cancer cells (TNBC), and studies showed that NAA20 could be targeted by TNBC cells to promote cell proliferation by activating EGFR signaling via Rab5A. Knockdown of NAA20 in vivo showed a decrease in tumor growth There are recent studies involving patients having mutations in the NAA20 gene, which were discovered by genetic screening. These patient mutations were found to affect the enzymatic properties of NatB thus probably being the cause of the various symptoms affecting their lives. These mutations are rare, involving only seven individuals from three different families reported so far, but all various mutations that have been found are on the NAA20 gene.
== Personal life == He married Margaret (Jennie) Jenkins and had two sons, Paul and Simon. Following the death in 1976 of his son Paul, guitarist with the band Free and later with Back Street Crawler, Kossoff established the Paul Kossoff Foundation which aimed to present the realities of drug addiction to children. Kossoff spent the remainder of his life campaigning against drugs. In the late 1970s and early 1980s, he toured with a one-man stage performance about the death of his son and its effect on the family. He died in 2005 of liver cancer at age 85. In its obituary, The Scotsman wrote that David Kossoff was "a man of deep convictions and proud of his Jewish origins".
=== Use in supplements aimed at eye health === In 2013, the Age-Related Eye Disease Study 2 (AREDS2) reported a reduced risk of visual loss and a reduced risk of disease progression over 5 years in 4,200 participants with early or moderate age-related macular degeneration (AMD) who were supplemented with a formulation containing the macular carotenoids and co-antioxidants. The AREDS2 preparation contained only two of the macular pigment’s three carotenoids (lutein and 3R,3´R-zeaxanthin), and did not include meso-zeaxanthin, which is the dominant carotenoid at the centre of the macula, the presence of which is essential for maximum collective antioxidant effect. Studies have shown that the addition of meso-zeaxanthin to formulations used to increase MP and enhance visual function in diseased and healthy retinas has proven effective. Trials have shown that a formulation containing all three macular carotenoids in a meso-zeaxanthin:lutein:zeaxanthin (mg) ratio of 10:10:2 is superior to alternative formulations, in terms of visual improvements and in observed increases in MP.
However, NAPE-PLD had no ability to produce detectable phosphatidic acid from phosphatidylcholine or phosphatidylethanolamine as is catalyzed by other phospholipase D enzymes. It also lacks the transphosphatidylation activity of phospholipase D that allows the creation of phosphatidyl alcohols rather than phosphatidic acid in the presence of ethanol or butanol.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
Dihexa has been reported to activate hepatocyte growth factor/c-Met signaling in cell studies. This pathway is linked to synapse formation and neuronal remodeling. The exact molecular interactions are not fully understood.